Skip to main content
. 2014 Aug 22;5(19):8893–8905. doi: 10.18632/oncotarget.2360

Figure 4. Silencing MUC1-C reverses EMT and KRAS independence.

Figure 4

(A and B) Lysates from A549 (A) and H460 (B) cells expressing CshRNA or MUC1shRNA were immunoblotted with the indicated antibodies. (C and D) A549 and H460 cells were left untreated or treated with 10 μM GSK690693 for 48 h. Lysates were immunoblotted with the indicated antibodies. (E and F) Lysates from A549 (E) and H460 (F) cells expressing CshRNA or MUC1shRNA were immunoblotted with the indicated antibodies. (G and H) A549/CshRNA and A549/MUC1shRNA (G) or H460/CshRNA and H460/MUC1shRNA (H) cells were infected twice over 24 h with lentivirus expressing a KRAS shRNA. At 48 h post-infection, cells were (i) collected for immunoblotting with the indicated antibodies (left) or (ii) plated at a density of 5 × 104 in a 6-well plate. The results (mean±SD of three replicates) are expressed as percent cell death as determined by trypan blue exclusion on day 4 (right).